[go: up one dir, main page]

HN2003000112A - Comprimido masticable con sabor agradable - Google Patents

Comprimido masticable con sabor agradable

Info

Publication number
HN2003000112A
HN2003000112A HN2003000112A HN2003000112A HN2003000112A HN 2003000112 A HN2003000112 A HN 2003000112A HN 2003000112 A HN2003000112 A HN 2003000112A HN 2003000112 A HN2003000112 A HN 2003000112A HN 2003000112 A HN2003000112 A HN 2003000112A
Authority
HN
Honduras
Prior art keywords
flavor
masticable
compressed
cetirizine
chewable tablet
Prior art date
Application number
HN2003000112A
Other languages
English (en)
Inventor
Kasraian Kasra
Havlir Tanya
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HN2003000112A publication Critical patent/HN2003000112A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE SE REFIERE A UN COMPRIIMIDO MASTICABLE ORAL, EN PARTICULAR UN COMPRIMIDO MASTICABLE QUE PROPRCIONA UN SABOR AGRADABLE PARA ENMASCARAR EL SABOR AMARGO DE UN AGENTE FARMACEUTICO CONTENIDO EN EL. LA CETIRIZINA ES UN NOMBRE GENERICO PARA EL ACIDO 2-[2-[[4-[(CLOROFENIL)FENILMETIL]-1-PIPERAZINIL]}ETOXI]- ACETICO Y SE PROPORCIONA TIPICAMENTE COMO SAL DIHIDROCLORURO. LA CETIRIZINA ES UN ANTAGONISTA RECEPTOR DE H1 ORALMENTE ACTIVO ACTUALMENTE PRESCRITO PARA EL TRATAMIENTO DE ALERGIAS ESTACIONALES EN PACIENTES DE DOS AÑOS DE EDAD Y MAYORES.
HN2003000112A 2002-04-04 2003-04-03 Comprimido masticable con sabor agradable HN2003000112A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37008602P 2002-04-04 2002-04-04

Publications (1)

Publication Number Publication Date
HN2003000112A true HN2003000112A (es) 2004-05-05

Family

ID=28792024

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2003000112A HN2003000112A (es) 2002-04-04 2003-04-03 Comprimido masticable con sabor agradable

Country Status (23)

Country Link
US (1) US7482022B2 (es)
EP (1) EP1494654B1 (es)
JP (1) JP2005526104A (es)
KR (1) KR20040098036A (es)
CN (1) CN100335041C (es)
AR (1) AR039242A1 (es)
AT (1) ATE388693T1 (es)
BR (1) BR0308927A (es)
CA (1) CA2481025A1 (es)
DE (1) DE60319685T2 (es)
ES (1) ES2298540T3 (es)
HN (1) HN2003000112A (es)
IL (1) IL164106A0 (es)
MX (1) MXPA04009617A (es)
NO (1) NO20044774L (es)
PA (1) PA8570601A1 (es)
PE (1) PE20030950A1 (es)
PL (1) PL372904A1 (es)
RU (1) RU2004129573A (es)
TW (1) TW200401651A (es)
UY (1) UY27746A1 (es)
WO (1) WO2003084511A1 (es)
ZA (1) ZA200407537B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101005648B1 (ko) * 2002-01-15 2011-01-05 유씨비 파쉼 소시에떼아노님 제형
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
WO2005105785A2 (en) 2004-05-04 2005-11-10 Novo Nordisk A/S Indole derivatives for treatment of obesity
CA2574602A1 (en) * 2004-07-22 2006-02-02 Pfizer Products Inc. Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
LT2522365T (lt) 2004-11-24 2017-02-10 Meda Pharmaceuticals Inc. Kompozicijos, apimančios azelastiną, ir jų panaudojimo būdai
WO2007144902A1 (en) * 2006-06-12 2007-12-21 Jubliant Organosys Limited Chewable bilayer tablet formulation
DK2178521T3 (da) * 2007-07-11 2014-04-28 Fertin Pharma As Stabilt medicinsk tyggegummi omfattende cyclodextrin-inklusionskompleks
WO2009006892A1 (en) * 2007-07-11 2009-01-15 Fertin Pharma A/S Stable medicated chewing gum comprising antioxidant
EP2178522A1 (en) * 2007-07-11 2010-04-28 Fertin Pharma A/S Compressed chewing gum tablet comprising taste-masking agent
CL2008003230A1 (es) * 2007-11-01 2009-11-27 Sanofi Aventis Healthcare Pty Ltd Composicion de recubrimiento de tableta que comprende polimero celulosico, plastificante, edulcorante y composicion de sabor en polvo la que comprende saborizante asociado con portador solido; fluido de recubrimiento de tableta que comprende dicha composicion; tableta farmaceutica; proceso de preparacion de dicha tableta.
BR112012011726A2 (pt) 2009-11-13 2020-05-19 Bristol-Myers Squibb Company comprimidos de duas camadas, seu uso, e suas combinações farmacêuticas
WO2011110939A2 (en) 2010-03-11 2011-09-15 Rubicon Research Private Limited Pharmaceutical compositions of substituted benzhydrylpiperazines
WO2013129436A1 (ja) * 2012-02-29 2013-09-06 武田薬品工業株式会社 経口剤
RS59365B1 (sr) 2012-06-15 2019-11-29 Pharmathen Sa Farmaceutska kompozicija koja sadrži polimer koji vezuje fosfat
CN102716099B (zh) * 2012-07-05 2013-10-09 湖南千金湘江药业股份有限公司 盐酸左西替利嗪咀嚼片及其制备方法
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
JP2016094364A (ja) * 2014-11-14 2016-05-26 ニプロ株式会社 安定化および苦味抑制された口腔内崩壊製剤
EP3061501A1 (en) 2015-02-27 2016-08-31 Rottapharm Ltd. Composition for the treatment of acne
EP3117825A1 (en) 2015-07-16 2017-01-18 Rottapharm S.p.A. Oral formulation comprising berberine and morus alba extract
JP2019001730A (ja) * 2017-06-13 2019-01-10 武田テバファーマ株式会社 安定な経口医薬組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558600A (en) 1967-07-28 1971-01-26 Abbott Lab Alkyl sulfate salts of 1-(p-chlorobenzhydryl)-4-methylhomopiperazines
NO155805C (no) 1981-02-06 1987-06-10 Ucb Sa Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-(4-(difenylmethyl)-1-piperazinyl)-eddiksyrer og deres amider og ikke-toksiske salter.
US4650663A (en) 1983-07-20 1987-03-17 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of antitussives
US4792448A (en) 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
IL91398A (en) 1988-08-30 1994-05-30 Pfizer Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
DK0542926T3 (da) 1990-08-07 1995-05-15 Pfizer Brug af grænsefladepolymeriserede membraner i frigivelsesanordninger
NZ256346A (en) 1992-10-09 1997-04-24 Procter & Gamble Medicaments containing 3-l-menthoxypropane-1,2-diol for treating cold symptoms
BE1011045A3 (fr) * 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
US6027746A (en) * 1997-04-23 2000-02-22 Warner-Lambert Company Chewable soft gelatin-encapsulated pharmaceutical adsorbates
BE1011251A3 (fr) * 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
DE19814256A1 (de) * 1998-03-31 1999-10-07 Asta Medica Ag Feste, schnellzerfallende Cetirizin-Formulierungen
US6270790B1 (en) 1998-08-18 2001-08-07 Mxneil-Ppc, Inc. Soft, convex shaped chewable tablets having reduced friability
US7223421B2 (en) * 2000-06-30 2007-05-29 Mcneil-Ppc, Inc. Teste masked pharmaceutical particles
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
KR101005648B1 (ko) * 2002-01-15 2011-01-05 유씨비 파쉼 소시에떼아노님 제형

Also Published As

Publication number Publication date
AR039242A1 (es) 2005-02-16
NO20044774L (no) 2004-11-03
ATE388693T1 (de) 2008-03-15
TW200401651A (en) 2004-02-01
WO2003084511A1 (en) 2003-10-16
PA8570601A1 (es) 2003-12-10
ZA200407537B (en) 2006-06-28
DE60319685D1 (de) 2008-04-24
EP1494654A1 (en) 2005-01-12
AU2003209953A1 (en) 2003-10-20
IL164106A0 (en) 2005-12-18
RU2004129573A (ru) 2005-04-10
US20030215503A1 (en) 2003-11-20
EP1494654B1 (en) 2008-03-12
PL372904A1 (en) 2005-08-08
ES2298540T3 (es) 2008-05-16
MXPA04009617A (es) 2005-01-11
JP2005526104A (ja) 2005-09-02
UY27746A1 (es) 2003-10-31
CN100335041C (zh) 2007-09-05
PE20030950A1 (es) 2003-11-12
CN1642531A (zh) 2005-07-20
KR20040098036A (ko) 2004-11-18
DE60319685T2 (de) 2009-03-26
CA2481025A1 (en) 2003-10-16
BR0308927A (pt) 2005-01-04
US7482022B2 (en) 2009-01-27

Similar Documents

Publication Publication Date Title
HN2003000112A (es) Comprimido masticable con sabor agradable
Meltzer et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial
Bernstein Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability
ES2302742T3 (es) Pulverizador nasal para suministrar una composicion farmaceutica.
AR062320A1 (es) Formulaciones de flibanserina y metodo para fabricarlas
WO2016062283A1 (zh) 抗发炎用药物在制备抑制癌症的医药组合物中的应用
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
PE20040134A1 (es) Forma de dosificacion de una vez al dia de pramipexol
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
CO6220962A2 (es) Usos terapeuticos novedosos de 1-[2(2,4-dimetilfenilsulfanil)fenil]-piperazina
RU2686670C2 (ru) Лечение аллергического ринита с использованием комбинации мометазона и олопатадина
US20080139654A1 (en) Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
RU2010105122A (ru) Композиции для ухода за полостью рта, продукты и способы применения
NO20065878L (no) Terapeutiske forbindelser
Dykewicz et al. Fluticasone propionate aqueous nasal spray improves nasal symptoms of seasonal allergic rhinitis when used as needed (prn)
JP2019031551A (ja) 女性胃不全麻痺に関係する症状の処置
US12194021B2 (en) Modified herbal compositions for neuromodulation
NO20080244L (no) Doseringsstyring for prasugrel
US6521254B2 (en) Single-dose antihistamine/decongestant formulations for treating rhinitis
KR102199560B1 (ko) 니코틴성 아세틸콜린 수용체 작용제로 부비점막 질환을 치료하기 위한 조성물 및 방법
US20190388370A1 (en) Treatment of symptoms associated with female gastroparesis
CN118078835A (zh) 用于夜间尿频的治疗剂
JP2009539893A (ja) 組合せウェーハ
ES2323646T3 (es) Uso de derivados de pirrol contra la ansiedad.
BR0312854A (pt) Compostos 1-fenil-2-dimetilaminometilciclohexano para a terapia de sintomas de depressão, dor e incontinência